Drug Watch

Positive phase 2 results show that treatment with alixorexton led to statistically significant and dose-dependent improvements in sleep latency among patients with narcolepsy type 1.

BioXcel Therapeutics has submitted an pre-sNDA meeting package for Igalmi's outpatient use, aiming to enhance treatment options for agitation in bipolar disorders and schizophrenia.

Gus Alva, MD, discusses the FDA committee vote on brexpiprazole for PTSD, what it means, and what's next.

The FDA advisory committee votes against brexpiprazole plus sertraline for PTSD, citing insufficient efficacy despite some positive trial results.

Seaport Therapeutics initiates a pivotal study for GlyphAllo, a potential breakthrough treatment for major depressive disorder, with or without anxious stress.

FDA reviewers raise concerns over Rexulti's efficacy for PTSD, highlighting discordant study results ahead of the advisory committee meeting.

The FDA advisory committee will review brexpiprazole for PTSD treatment, which could offer new hope after years without new options.

Transcend Therapeutic announces breakthrough therapy designation for TSND-201 for treating PTSD.

Johnson & Johnson has submitted an sNDA for Caplyta, showcasing significant relapse prevention in schizophrenia.

What disease states are most prominently featured in recent research? Learn more in this exclusive article.

New clinical trial results reveal BPL-003's rapid and durable antidepressant effects, paving the way for innovative treatments in treatment-resistant depression.

The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals.

Check out the pipeline updates from June!

Alto Neuroscience's ALTO-203 trial reveals mixed results, highlighting potential biomarkers for targeted depression treatment despite missing primary efficacy goals.

Compass Pathways reports significant progress in psilocybin research, showing promise for treatment-resistant depression in a pivotal phase 3 trial.

NRx Pharmaceuticals advances NRX-100, a preservative-free ketamine, through a fast-tracked FDA review for treating suicidal depression and PTSD.

Ecopipam shows promise as a safe, effective treatment for Tourette syndrome in children and adolescents, significantly reducing tic severity and improving quality of life.

The FDA's removal of clozapine REMS enhances access to treatment, while new educational initiatives empower clinicians to improve patient care.

The RECOVER open label trial demonstrated positive results for brilaroxazine for schizophrenia.

Check out the pipeline updates from May!

Cariprazine shows promise as a long-term adjunctive treatment for anhedonia in major depressive disorder, according to new poster data presented at the ASCP Annual Meeting.

Neurocrine Biosciences reveals promising phase 2 results for NBI-1117568, a novel treatment for schizophrenia, showing significant symptom improvement over placebo.

Promising results from a phase 2 study of CPL'36, a novel PDE10A inhibitor, for acute schizophrenia exacerbation was presented at the APA annual meeting.

Dana Hilt, MD, PhD, discusses data on Xanamem’s impact on cortisol and its potential use in MDD at the APA Annual Meeting.

New analyses reveal valbenazine (Ingrezza) significantly enhances quality of life and functional outcomes for patients with tardive dyskinesia, supporting its long-term efficacy.